Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 99
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 80 more

Conditions: Alzheimer's Disease
Interventions: J147, Placebo; Drug
Lead sponsor: Abrexa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Food Effect in Healthy Volunteers
Interventions: PBI-200; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy Volunteer Study
Interventions: Fixed-Dose Combination (FDC) Tablet; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Chronic Pain, Depression, PTSD Symptoms, Sleep
Interventions: Traditional Chinese Acupuncture, Tennant™ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment; Other · Device
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Impulse Control Disorder, Parkinson Disease
Interventions: rTMS Active, rTMS Sham; Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pain
Interventions: Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: Bipolar Disorder, Circadian Rhythm, Depressive Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Female only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lupus Nephritis
Interventions: LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid; Drug · Biological
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 27
States / cities: La Mesa, California • Los Alamitos, California • Arvada, Colorado + 23 more

Conditions: Type 1 Diabetes Mellitus
Interventions: InsuPatch; Device
Lead sponsor: Insuline Medical Ltd.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Food Choices
Interventions: Control (QR Code) Menu Labels, Traffic-Light Style Environmental Harm Menu Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 64 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: Oral Glucose Tolerance Test (OGTT), Assessment of dietary compliance, Stool sampling, Sodium Saccharin, Placebo, Lactisole; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pulmonary Embolism
Interventions: Outpatient Treatment of Pulmonary Embolism; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions: Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin; Device · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cerebral Edema, Diabetic Ketoacidosis
Interventions: 0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 1,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more

Conditions: Calibration and Validation of Analyte Testing System
Interventions: Minimally invasive and non-invasive blood analyte measurement; Diagnostic Test
Lead sponsor: Kaligia Biosciences, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Timeline: 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Depersonalization Disorder
Interventions: Daily rTMS with Active coil, Daily rTMS with Sham coil, Open Label Daily rTMS with Active coil; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: New York, New York

Conditions: Vascular Access Complications
Interventions: AccuCath IV Catheter System, Conventional IV Catheter System; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers, Fasting, Fed
Interventions: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®); Drug
Lead sponsor: TAHO Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Parkinson Disease
Interventions: Ketone Ester Beverage, Electrolyte Beverage, Cycling Intervention; Dietary Supplement · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bloodstream Infection
Interventions: Accelerate PhenoTest™ BC kit, Standard of Care; Diagnostic Test
Lead sponsor: Accelerate Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Effects of Sex Hormones on Circadian Rhythm in Men and Women

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Pediatric Diabetics Type 1 Using InsuPatch

Environmental Harm Menu Labels and Overall Dietary Quality

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

Outpatient Treatment of Low-risk Pulmonary Embolism

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis

A Human Clinical Study to Collect Calibration and Performance Data for the RBA-1 and KBS-1

Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)

Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures